Mirova US LLC Has $219.47 Million Position in Edwards Lifesciences Corporation $EW

Mirova US LLC decreased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 3.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,822,092 shares of the medical research company’s stock after selling 109,205 shares during the period. Edwards Lifesciences comprises about 2.2% of Mirova US LLC’s holdings, making the stock its 20th largest holding. Mirova US LLC owned about 0.48% of Edwards Lifesciences worth $219,474,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Econ Financial Services Corp acquired a new position in shares of Edwards Lifesciences during the 2nd quarter valued at $889,000. Randolph Co Inc bought a new stake in Edwards Lifesciences in the second quarter valued at $301,000. OMERS ADMINISTRATION Corp increased its stake in Edwards Lifesciences by 97.3% in the second quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock valued at $3,481,000 after purchasing an additional 21,950 shares in the last quarter. Arkadios Wealth Advisors acquired a new position in shares of Edwards Lifesciences during the second quarter valued at about $300,000. Finally, Pacific Capital Partners Ltd bought a new position in shares of Edwards Lifesciences during the 2nd quarter worth about $1,760,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 11,386 shares of Edwards Lifesciences stock in a transaction on Friday, December 12th. The stock was sold at an average price of $83.76, for a total value of $953,691.36. Following the completion of the transaction, the vice president directly owned 38,970 shares in the company, valued at approximately $3,264,127.20. The trade was a 22.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $84.03, for a total value of $85,626.57. Following the sale, the vice president owned 22,002 shares in the company, valued at approximately $1,848,828.06. This represents a 4.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 45,465 shares of company stock valued at $3,804,610 over the last three months. 0.34% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $86.94 on Tuesday. The firm has a market capitalization of $50.45 billion, a P/E ratio of 37.47, a price-to-earnings-growth ratio of 3.90 and a beta of 0.97. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. The business’s fifty day simple moving average is $84.08 and its 200 day simple moving average is $79.71. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The company had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The business’s revenue for the quarter was up 14.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on EW shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Wednesday, October 8th. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $90.00 target price on shares of Edwards Lifesciences in a research report on Monday, November 3rd. JPMorgan Chase & Co. upgraded Edwards Lifesciences from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $90.00 to $100.00 in a report on Thursday, December 18th. Jefferies Financial Group set a $98.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Wednesday, October 29th. Finally, Raymond James Financial upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price objective on the stock in a report on Monday, November 3rd. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $93.95.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.